Drug Profile
Betahistine intranasal - Altamira Therapeutics
Alternative Names: AM 125; AM-201 - Altamira Therapeutics; Betahistine dihydrochloride - Altamira TherapeuticsLatest Information Update: 19 Jun 2023
Price :
$50
*
At a glance
- Originator University of Melbourne
- Developer Altamira Therapeutics; Otifex Therapeutics
- Class Amines; Anti-inflammatories; Antidementias; Pyridines; Small molecules; Vestibular disorder therapies
- Mechanism of Action Histamine H1 receptor agonists; Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Vertigo
Highest Development Phases
- Suspended Meniere's disease; Vertigo; Weight gain
- Discontinued Otitis
Most Recent Events
- 15 Jun 2023 US FDA approves IND application for Betahistine intranasal in Posterior canal benign paroxysmal positional vertigo (BPPV)
- 15 Jun 2023 Altamira Therapeutics plans a phase II trial for Posterior canal benign paroxysmal positional vertigo (BPPV) in USA
- 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in Vertigo in Unknown (PO)